Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rapid Improvement Seen With Nemolizumab For Prurigo Nodularis in Phase 2b Study

Key clinical point: Interleukin-31 signaling is a promising therapeutic target in prurigo nodularis.

Major finding: Four weeks after their first monthly dose of nemolizumab, patients with severe prurigo nodularis averaged a 53.4% reduction in peak pruritus scores, compared with 15.3% in placebo-treated controls.

Study details: This phase 2b, double-blind, randomized, 18-week, 20-center European trial included 70 patients with severe prurigo nodularis.

Disclosures: The study was sponsored by Galderma. The presenter has served as a consultant to that company and numerous other pharmaceutical companies.

Citation:

Stander S. EADV Congress, late-breaker.